Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution
pharmaceutical investing Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing
Triumph Gold's Executive Chairman Discusses Utah Silver-Gold Acquisition and Exploration Strategy in New INN CEO Insights Interview
